| 汪继苗,姜 舒,仲雅婷,龙玲艳,汪海岩.血清ANXA2、ANXA3与转移性结直肠癌患者化疗疗效的关系[J].现代生物医学进展英文版,2024,(2):324-328. |
| 血清ANXA2、ANXA3与转移性结直肠癌患者化疗疗效的关系 |
| Relationship between Serum ANXA2, ANXA3 and the Efficacy of Chemotherapy in Patients with Metastatic Colorectal Cancer |
| Received:June 07, 2023 Revised:June 29, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.02.023 |
| 中文关键词: 膜联蛋白A2 膜联蛋白A3 转移性结直肠癌 化疗 疗效 |
| 英文关键词: Annexin A2 Annexin A3 Metastatic colorectal cancer Chemotherapy Efficacy |
| 基金项目:江苏省人社厅第十四批"六大人才高峰"高层次人才项目（WSN-121） |
|
| Hits: 292 |
| Download times: 262 |
| 中文摘要: |
| 摘要 目的：探讨血清膜联蛋白（ANX）A2、ANXA3与转移性结直肠癌（mCRC）患者化疗疗效的关系。方法：选取2019年1月～2020年10月徐州医科大学附属医院收治的90例mCRC患者，根据mFOLFOX6化疗联合西妥昔单抗治疗后的疗效分为未缓解组和缓解组。采用酶联免疫吸附法检测血清ANXA2、ANXA3水平。分别采用单因素、多因素Logistic回归分析和受试者工作特征（ROC）曲线分析mCRC患者化疗未缓解的影响因素和血清ANXA2、ANXA3对mCRC患者化疗未缓解的预测价值。结果：90例mCRC患者客观缓解率为58.89%（53/90）。单因素分析显示，两组年龄、回盲部肿瘤、TNM分期、Zubrod-东部肿瘤协助组-世界卫生组织（ZPS）评分、治疗目标、ANXA2、ANXA3组间比较存在统计学差异（P＜0.05）。多因素Logistic回归分析显示，回盲部肿瘤、TNM分期Ⅳ期、ZPS评分1～2分和ANXA2、ANXA3升高为mCRC患者化疗未缓解的独立危险因素（P＜0.05）。ROC曲线分析显示，血清ANXA2预测mCRC患者化疗未缓解的曲线下面积（AUC）为0.787，ANXA3预测mCRC患者化疗未缓解的AUC为0.791，血清ANXA2、ANXA3联合预测为0.904，二者联合预测的AUC最大（P＜0.05）。结论：血清ANXA2、ANXA3水平升高为mCRC患者化疗未缓解的独立危险因素，可影响mCRC患者的化疗疗效，二者联合预测mCRC患者化疗未缓解的价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum annexin (ANX) A2, ANXA3 and the efficacy of chemotherapy in patients with metastatic colorectal cancer (mCRC). Methods: 90 mCRC patients who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2019 to October 2020 were selected, patients were divided into non-remission group and remission group according to the efficacy of mFOLFOX6 chemotherapy combined with cetuximab. Serum ANXA2 and ANXA3 levels were detected by enzyme-linked immunosorbent assay. Using univariate, multivariate logistic regression analysis, and receiver operating characteristic (ROC) curve analysis, respectively, the influencing factors of unresponsive chemotherapy in mCRC patients and the predictive value of serum ANXA2 and ANXA3 on unresponsive chemotherapy in mCRC patients. Results: The objective remission rate of 90 mCRC patients was 58.89% (53/90). Univariate analysis showed that statistical differences between the two groups in terms of age, ileocecal tumor, TNM stage, Zubrod-Eastern Tumor Assistance Group-World Health Organization score (ZPS), treatment goal, ANXA2 and ANXA3 (P<0.05). Multivariate Logistic regression analysis showed that, ileocecal tumor, TNM stage IV, ZPS score 1-2 and increased ANXA2 and ANXA3 were independent risk factors of non-remission in mCRC patients (P<0.05). The ROC curve analysis showed that the area under the curve (AUC) predicted by serum ANXA2 was 0.787. The ROC curve analysis showed that the AUC that predicted by ANXA3 was 0.791, and that predicted by serum ANXA2 and ANXA3 was 0.904. The AUC predicted by serum ANXA2 and ANXA3 was the largest (P<0.05). Conclusion: Increase serum ANXA2 and ANXA3 levels are independent risk factors of chemotherapy non-remission in mCRC patients, which can affect the efficacy of chemotherapy in mCRC patients, and combination of the two has a higher value in predicting chemotherapy non-remission in mCRC patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
